Cholera Clinical Trial
Official title:
Targeted Vaccination of Children in Urban Slums Against Cholera: Evaluation of a Potentially Cost-effective and Impactful Strategy for Deploying Oral Cholera Vaccine in Bangladesh
To evaluate the preventive impact, demand, acceptability, uptake, feasibility, and cost-effectiveness of a two-dose regimen of the OCV Shanchol in children living in urban slums in Bangladesh, Investigators will conduct a targeted mass immunization programme, using an innovative approach successfully deployed by the Bangladesh government in its recent countrywide campaign of MR vaccination of 52 million children aged 9 months to 14 years (<15 years). Investigators will undertake a census of a geographic population of approximately 300,000 persons, with GIS locations of each household. This census will be updated every 6 months during the follow-up period to permit tracking of births, deaths, and migrations, including changes in location of each individual's residence. Following the initial census, the OCV will be offered to all non-pregnant individuals aged 1 to 14 years. Operational research and economic studies will evaluate the coverage, feasibility, acceptability, demand, costs and cost-effectiveness of this vaccination programme.
Burden: Cholera remains a major global problem, resulting in more than 100,000 deaths and
several million cases annually , mostly children. Vaccination has been reconsidered as a key
component of the public health response to cholera. Bangladesh has one of the world's highest
burdens of endemic cholera, with an estimated 300,000 cholera cases and over 4,500 deaths
annually, and with high caseloads and frequent outbreaks in more than half of the country.
The endemicity of cholera in Bangladesh is demonstrated by the predictable yearly occurrence
of the disease in the country's high-risk districts and the repetitive seasonal pattern of
cholera outbreaks, either in spring or autumn, or both .
Knowledge gap: More evidence is needed to address uncertainties around the cholera disease
burden, as well as the impact, feasibility, and cost-effectiveness of various vaccination
strategies against cholera, to add to the existing knowledge base. A special need for
acquiring field evidence of these vaccine attributes in settings with endemic cholera, which
account for a very large fraction of the global cholera disease burden, is also recognized .
Relevance: Nonetheless, the assertion that selective vaccination of children with OCV is an
impactful approach to controlling cholera at the population level rests on unproven
assumptions, since there are no studies that directly address this vaccination strategy.
Therefore, further study on whether targeted mass immunization can create efficiencies that
general mass immunization would not, is warranted. The Investigators therefore believe that
the most compelling question for the control of endemic cholera in Bangladesh is how
targeting 1-14 year olds in urban slums, using the established platform of targeted mass
childhood immunization recently deployed by the GOB for measles-rubella (MR) vaccine, impacts
on the overall burden of cholera in the population and how feasible and cost-effective this
strategy is. Addressing these questions will add to the evidence base on the most cost
efficient and effective settings and strategies for use of OCV to control endemic disease and
optimize health impact.
Hypothesis : Vaccination of children under 15 years of age in urban slums of Dhaka will
confer at least 50% overall protection to the entire population through combined direct and
indirect protective effects and it will be cost effective.
Objectives:To evaluate the feasibility, efficiency, and impact of a two-dose regimen of the
oral cholera vaccine (OCV) Shanchol delivered to children aged 1-14 years residing in urban
slums, leveraging a targeted mass immunization delivery platform used for other vaccines in
Bangladesh.
Methods: Observational design based on the contrast of persons who do and do not get
vaccinated according to public health practice(Age-targeted mass immunization program).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01895855 -
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
|
Phase 3 | |
Completed |
NCT01339845 -
Introduction of Cholera Vaccine in Bangladesh
|
N/A | |
Recruiting |
NCT05829772 -
Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
|
||
Completed |
NCT04760236 -
Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shancholâ„¢
|
Phase 3 | |
Recruiting |
NCT04326478 -
Single Dose Azithromycin to Prevent Cholera in Children
|
Phase 2 | |
Recruiting |
NCT06104345 -
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
|
Phase 4 | |
Completed |
NCT02928341 -
Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo
|
N/A | |
Completed |
NCT02864433 -
Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
|
||
Recruiting |
NCT06003816 -
Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)
|
N/A | |
Not yet recruiting |
NCT05771779 -
Co-administration Study of OCV, TCV and MR
|
Phase 3 | |
Not yet recruiting |
NCT06455852 -
Correlates of Protection for Cholera
|
N/A | |
Completed |
NCT04150250 -
Cholera Anti-Secretory Treatment Trial
|
Phase 2 | |
Terminated |
NCT00624975 -
Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants
|
Phase 2 | |
Completed |
NCT00226616 -
Zinc Supplementation in Cholera Patients
|
Phase 3 | |
Completed |
NCT03373669 -
Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine
|
Phase 4 | |
Completed |
NCT02100631 -
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
|
Phase 3 | |
Completed |
NCT02094586 -
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
|
Phase 3 | |
Completed |
NCT01823939 -
PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera
|
Phase 1 | |
Completed |
NCT01365442 -
Pilot Introduction of Oral Cholera Vaccine in Orissa, India
|
N/A | |
Completed |
NCT00128011 -
Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine
|
Phase 2 |